Drug Manufacturing

Sandoz to acquire GlaxoSmithKline’s cephalosporin antibiotics business

Global leader in antibiotics and a division of Swiss multinational pharma company Novartis, Germany-based Sandoz has signed a contract to acquire GlaxoSmithKline’s (GSK) cephalosporin antibiotics.

AstraZeneca signs LOI with IDT Biologika to boost Europe’s Covid-19 vaccine-making capability

Cambridge-based global, science-led biopharmaceutical company AstraZeneca and German manufacturer of viral vaccines and biologics IDT Biologika have signed a Letter of Intent (LOI) to increase Europe’s Covid-19 vaccine manufacturing capability.

USFDA approves EUA for bamlanivimab-etesevimab combo to treat Covid-19 patients

The U.S. Food and Drug Administration (FDA) has approved Emergency Use Authorization (EUA) for investigational bamlanivimab and etesevimab as a combination therapy for the treatment of mild to moderate Covid-19 patients.

Ocugen signs agreement with Bharat Biotech to distribute Covid-19 vaccine in the US

Ocugen, a Pennsylvania-based pharmaceutical company, has signed an agreement with Bharat Biotech, an Indian pharma developer of COVAXIN, a Covid-19 vaccine, to distribute the vaccine in the US.

WuXi STA to buy Swiss pharma manufacturing facility from Bristol Myers Squibb

WuXi STA, a subsidiary of Chinese pharmaceutical company WuXi AppTec, has agreed to buy the Couvet, Switzerland-based manufacturing facility from Bristol Myers Squibb.

Sanofi to manufacture 125 million doses of Pfizer-BioNTech’s Covid-19 vaccine

French pharma giant Sanofi has entered into an agreement with BioNTech, to manufacture the Covid-19 vaccine co-developed by BioNTech and Pfizer.

Etana to launch Innovent Biologics’ cancer drug BYVASDA in Indonesia

Chinese pharmaceutical company Innovent Biologics has signed an out-license agreement with Etana Biotechnologies to develop and commercialise cancer drug BYVASDA (Bevacizumab Biosimilar) in Indonesia.

Thermo Fisher Scientific acquires viral vector business from Novasep for $875m

Thermo Fisher Scientific announced the acquisition of Henogen, a Belgian viral vector manufacturing business belonging to Groupe Novasep, for about €725m ($875m) in cash.

Fujifilm to invest $2bn to build large-scale cell culture manufacturing site in US

Fujifilm is set to invest about $2bn to build a new large-scale cell culture production site for biopharmaceuticals in the US.